Caribou Biosciences Analyst Ratings
Caribou Biosciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | — | Cantor Fitzgerald | Initiates Coverage On | → Neutral | |
| 07/26/2023 | 394.62% | HC Wainwright & Co. | $25 → $23 | Maintains | Buy |
| 07/14/2023 | 394.62% | Truist Securities | $23 → $23 | Reiterates | Buy → Buy |
| 07/11/2023 | 394.62% | Truist Securities | → $23 | Initiates Coverage On | → Buy |
| 05/10/2023 | 437.63% | HC Wainwright & Co. | $26 → $25 | Maintains | Buy |
| 03/14/2023 | 459.14% | HC Wainwright & Co. | $27 → $26 | Maintains | Buy |
| 03/10/2023 | 308.6% | RBC Capital | → $19 | Reiterates | → Outperform |
| 03/10/2023 | 588.17% | Oppenheimer | $36 → $32 | Maintains | Outperform |
| 08/29/2022 | 717.2% | Citigroup | $39 → $38 | Maintains | Buy |
| 08/18/2022 | 480.65% | HC Wainwright & Co. | $28 → $27 | Maintains | Buy |
| 08/10/2022 | 308.6% | RBC Capital | $22 → $19 | Maintains | Outperform |
| 05/13/2022 | 738.71% | Citigroup | $29 → $39 | Maintains | Buy |
| 05/12/2022 | 631.18% | SVB Leerink | $30 → $34 | Maintains | Outperform |
| 05/10/2022 | 545.16% | SVB Leerink | $29 → $30 | Maintains | Outperform |
| 03/22/2022 | 523.66% | SVB Leerink | $32 → $29 | Maintains | Outperform |
| 02/18/2022 | 373.12% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 02/14/2022 | 308.6% | Brookline Capital | → $19 | Initiates Coverage On | → Buy |
| 12/01/2021 | 674.19% | Oppenheimer | → $36 | Initiates Coverage On | → Outperform |
| 11/30/2021 | 502.15% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 11/15/2021 | 480.65% | Citigroup | → $27 | Upgrades | Neutral → Buy |
| 08/17/2021 | 480.65% | Citigroup | → $27 | Initiates Coverage On | → Neutral |
| 08/17/2021 | 545.16% | B of A Securities | → $30 | Initiates Coverage On | → Buy |
| 08/17/2021 | 588.17% | SVB Leerink | → $32 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/08/2023 | — | 坎託·菲茨傑拉德 | 啓動覆蓋範圍開啓 | → 中立 | |
| 07/26/2023 | 394.62% | HC Wainwright & Co. | 25 美元 → 23 美元 | 維護 | 買 |
| 07/14/2023 | 394.62% | Truist 證券 | 23 美元 → 23 美元 | 重申 | 購買 → 購買 |
| 07/11/2023 | 394.62% | Truist 證券 | → 23 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/10/2023 | 437.63% | HC Wainwright & Co. | 26 美元 → 25 美元 | 維護 | 買 |
| 03/14/2023 | 459.14% | HC Wainwright & Co. | 27 美元 → 26 美元 | 維護 | 買 |
| 03/10/2023 | 308.6% | 加拿大皇家銀行資本 | → 19 美元 | 重申 | → 跑贏大盤 |
| 03/10/2023 | 588.17% | 奧本海默 | 36 美元 → 32 美元 | 維護 | 跑贏大盤 |
| 08/29/2022 | 717.2% | 花旗集團 | 39 美元 → 38 美元 | 維護 | 買 |
| 08/18/2022 | 480.65% | HC Wainwright & Co. | 28 美元 → 27 美元 | 維護 | 買 |
| 08/10/2022 | 308.6% | 加拿大皇家銀行資本 | 22 美元 → 19 美元 | 維護 | 跑贏大盤 |
| 05/13/2022 | 738.71% | 花旗集團 | 29 美元 → 39 美元 | 維護 | 買 |
| 05/12/2022 | 631.18% | SVB Leerink | 30 美元 → 34 美元 | 維護 | 跑贏大盤 |
| 05/10/2022 | 545.16% | SVB Leerink | 29 美元 → 30 美元 | 維護 | 跑贏大盤 |
| 03/22/2022 | 523.66% | SVB Leerink | 32 美元 → 29 美元 | 維護 | 跑贏大盤 |
| 2022 年 2 月 18 日 | 373.12% | 加拿大皇家銀行資本 | → 22 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 02/14/2022 | 308.6% | 布魯克林資本 | → 19 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 12/01/2021 | 674.19% | 奧本海默 | → 36 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 11 月 30 日 | 502.15% | HC Wainwright & Co. | → 28 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/15/2021 | 480.65% | 花旗集團 | → 27 美元 | 升級 | 中性 → 買入 |
| 2021 年 8 月 17 日 | 480.65% | 花旗集團 | → 27 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 2021 年 8 月 17 日 | 545.16% | B of A 類證券 | → 30 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 8 月 17 日 | 588.17% | SVB Leerink | → 32 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Caribou Biosciences (CRBU)?
Caribou Biosciences (CRBU) 的目標價格是多少？
The latest price target for Caribou Biosciences (NASDAQ: CRBU) was reported by Cantor Fitzgerald on November 8, 2023. The analyst firm set a price target for $0.00 expecting CRBU to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年11月8日公佈了Caribou Biosciences（納斯達克股票代碼：CRBU）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計CRBU將在12個月內降至12個月內（可能下跌-100.00％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Caribou Biosciences (CRBU)?
Caribou Biosciences（CRBU）的最新分析師評級是多少？
The latest analyst rating for Caribou Biosciences (NASDAQ: CRBU) was provided by Cantor Fitzgerald, and Caribou Biosciences initiated their neutral rating.
Caribou Biosciences（納斯達克股票代碼：CRBU）的最新分析師評級由坎託·菲茨傑拉德提供，Caribou Biosciences啓動了中性評級。
When is the next analyst rating going to be posted or updated for Caribou Biosciences (CRBU)?
Caribou Biosciences（CRBU）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Caribou Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Caribou Biosciences was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Caribou Biosciences的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Caribou Biosciences的最新評級是在2023年11月8日公佈的，因此您應該預計下一個評級將在2024年11月8日左右公佈。
Is the Analyst Rating Caribou Biosciences (CRBU) correct?
分析師對 Caribou Biosciences (CRBU) 的評級正確嗎？
While ratings are subjective and will change, the latest Caribou Biosciences (CRBU) rating was a initiated with a price target of $0.00 to $0.00. The current price Caribou Biosciences (CRBU) is trading at is $4.65, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Caribou Biosciences（CRBU）評級最初是以0.00美元至0.00美元的目標股價爲起步的。Caribou Biosciences（CRBU）目前的交易價格爲4.65美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。